CXCR4 and neoplasm: Following in situ tumorigenesis in mice, we administered an CXCR4 inhibitor drug via injection into the prostate, resulting in a significant reduction in tumor size in the treated group compared to the control group, as indicated by fluorescence intensity measurements (Figure 8B).